Kazuo Takayama

Dr. Kazuo Takayama

Kyoto University
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TTTomokazu Tamura
Tomokazu Tamura
JIJumpei Ito
Jumpei Ito
KUKeiya Uriu
Keiya Uriu
JZJiri Zahradnik
Jiri Zahradnik
IKIzumi Kida
Izumi Kida
TUTakamasa Ueno
Takamasa Ueno
In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.

1 February 2013 in Biomaterials
Verified
Journal Article
Closed access
KTKazuo Takayama
Kazuo Takayama
KKKenji Kawabata
Kenji Kawabata
YNYasuhito Nagamoto
Yasuhito Nagamoto
KKKeisuke Kishimoto
Keisuke Kishimoto
KTKatsuhisa Tashiro
Katsuhisa Tashiro
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi

1 January 2012 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
KTKazuo Takayama
Kazuo Takayama
MIMitsuru Inamura
Mitsuru Inamura
KKKenji Kawabata
Kenji Kawabata
KKKazufumi Katayama
Kazufumi Katayama
MHMaiko Higuchi
Maiko Higuchi
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
Hepatocyte-like cells from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are expected to be a useful source of cells drug discovery. Although we recently reported that hepatic commitment is promoted by transduction of SOX17 and HEX into human ESC- and iPSC-derived cells, these hepatocyte-like cells were not sufficiently mature for drug screening. To promote hepatic maturation, we utilized transduction of the hepatocyte nuclear factor 4α (HNF4α) gene, which is known as a master regulator of liver-specific gene expression. Adenovirus vector-mediated overexpression of HNF4α in hepatoblasts induced by SOX17 and HEX transduction led to upregulation of epithelial and mature hepatic markers such as cytochrome P450 (CYP) enzymes, and promoted hepatic maturation by activating the mesenchymal-to-epithelial transition (MET). Thus HNF4α might play an important role in the hepatic differentiation from human ESC-derived hepatoblasts by activating the MET. Furthermore, the hepatocyte like-cells could catalyze the toxication of several compounds. Our method would be a valuable tool for the efficient generation of functional hepatocytes derived from human ESCs and iPSCs, and the hepatocyte-like cells could be used for predicting drug toxicity.

10 November 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KTKazuo Takayama
Kazuo Takayama
YMYuta Morisaki
Yuta Morisaki
SKShuichi Kuno
Shuichi Kuno
YNYasuhito Nagamoto
Yasuhito Nagamoto
KHKazuo Harada
Kazuo Harada
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
Significance: We found that individual cytochrome P450 (CYP) metabolism capacity and drug sensitivity could be predicted by examining them in the primary human hepatocytes–human induced pluripotent stem cells–hepatocyte-like cells (PHH-iPS-HLCs). We also confirmed that interindividual differences of CYP metabolism capacity and drug responsiveness that are due to the diversity of individual single nucleotide polymorphisms in the CYP gene could also be reproduced in the PHH-iPS-HLCs. These findings suggest that interindividual differences in drug metabolism capacity and drug response could be predicted by using HLCs differentiated from human iPS cells. We believe that iPS-HLCs would be a powerful technology not only for accurate and efficient drug development, but also for personalized drug therapy.

1 August 2020 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
KTKazuo Takayama
Kazuo Takayama

2 December 2020 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
MSMurat Seyran
Murat Seyran
KTKazuo Takayama
Kazuo Takayama
VUVladimir N. Uversky
Vladimir N. Uversky
KLKenneth Lundstrom
Kenneth Lundstrom
GPGiorgio Palù
Giorgio Palù
BUBruce Uhal
Bruce Uhal
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of the pandemic coronavirus disease 2019 (COVID‐19) that exhibits an overwhelming contagious capacity over other human coronaviruses (HCoVs). This structural snapshot describes the structural bases underlying the pandemic capacity of SARS‐CoV‐2 and explains its fast motion over respiratory epithelia that allow its rapid cellular entry. Based on notable viral spike (S) protein features, we propose that the flat sialic acid‐binding domain at the N‐terminal domain (NTD) of the S1 subunit leads to more effective first contact and interaction with the sialic acid layer over the epithelium, and this, in turn, allows faster viral ‘surfing’ of the epithelium and receptor scanning by SARS‐CoV‐2. Angiotensin‐converting enzyme 2 (ACE‐2) protein on the epithelial surface is the primary entry receptor for SARS‐CoV‐2, and protein–protein interaction assays demonstrate high‐affinity binding of the spike protein (S protein) to ACE‐2. To date, no high‐frequency mutations were detected at the C‐terminal domain of the S1 subunit in the S protein, where the receptor‐binding domain (RBD) is located. Tight binding to ACE‐2 by a conserved viral RBD suggests the ACE2‐RBD interaction is likely optimal. Moreover, the viral S subunit contains a cleavage site for furin and other proteases, which accelerates cell entry by SARS‐CoV‐2. The model proposed here describes a structural basis for the accelerated host cell entry by SARS‐CoV‐2 relative to other HCoVs and also discusses emerging hypotheses that are likely to contribute to the development of antiviral strategies to combat the pandemic capacity of SARS‐CoV‐2.